Clinical Trials • Medical Writing • Translational Medicine • Cro • Cardiology • Clinical Pharmacology • Neuroscience • Medical Education • Neurology • Infectious Diseases • Genomics • Clinical Research • Ctms • Biotechnology • Immunology • Healthcare • Life Sciences • Hematology • Internal Medicine • Pharmacovigilance • Drug Discovery • Molecular Biology • Lifesciences • Medicine • Oncology • Drug Development • Gcp • Clinical Development • Pharmaceutics • Edc • Vaccines • Cancer • Regulatory Submissions • Pharmacology • Pharmaceutical Industry • Science • Biochemistry • Therapeutic Areas • Biomarkers • R&D • Fda • Sop • Commercialization • Medical Affairs • Biopharmaceuticals
Industries
Biotechnology
Name / Title
Company / Classification
Phones & Addresses
Hagop Youssoufian President, Research And Development Staff
Ziopharm Oncology Pharmaceuticals · Development Stage Company Engaged In The Development and Commercialization of A Portfolio of In-Licensed Cancer Drugs · Development Stage Company In Development and Commercialization of A Portfolio of In-Licensed Cancer Drugs · Pharmaceutical Preparations · Mfg Pharmaceutical Preparations
1 1 Avenue, Parris BUILDING #34, Boston, MA 02129 1180 Ave Of The, New York, NY 10036 1180 Ave, New York, NY 10036 1 1 Ave, Boston, MA 02129 6462140700
Bind Therapeutics Nov 1, 2014 - Aug 2016
Chief Medical Officer
Progenics Pharmaceuticals Jul 2013 - Sep 2014
Executive Vice President
Ziopharm Oncology Oct 2011 - Apr 2013
President of R and D and Chief Medical Officer
Independent Consultant Oct 2011 - Apr 2013
Consultant To Biotech Industry
Ziopharm Oncology Jul 2011 - Sep 2011
Chief Marketing Officer and Executive Vice President
Education:
Harvard Medical School 1987 - 1991
Whitehead Institute 1988 - 1991
The Johns Hopkins University School of Medicine 1985 - 1987
University of Massachusetts Medical School 1978 - 1983
Master of Science, Doctorates, Masters, Doctor of Medicine, Medicine
Boston College 1974 - 1978
Bachelors, Bachelor of Science, Biology
Skills:
Clinical Trials Medical Writing Translational Medicine Cro Cardiology Clinical Pharmacology Neuroscience Medical Education Neurology Infectious Diseases Genomics Clinical Research Ctms Biotechnology Immunology Healthcare Life Sciences Hematology Internal Medicine Pharmacovigilance Drug Discovery Molecular Biology Lifesciences Medicine Oncology Drug Development Gcp Clinical Development Pharmaceutics Edc Vaccines Cancer Regulatory Submissions Pharmacology Pharmaceutical Industry Science Biochemistry Therapeutic Areas Biomarkers R&D Fda Sop Commercialization Medical Affairs Biopharmaceuticals
Us Patents
Combination Therapy Including Isophosphoramide Mustard, Analogs, Or Salts Thereof
Jonathan LEWIS - Fairfield CT, US Hagop YOUSSOUFIAN - West Roxbury MA, US
Assignee:
ZIOPHARM ONCOLOGY, INC. - Boston MA
International Classification:
A61K 31/7048 A61K 31/555 A61K 31/664
US Classification:
424649, 514 27
Abstract:
In one aspect, a method for treating a subject having a hyperproliferative disorder is disclosed, including administering to the subject a composition including: IPM, an IPM analog, or a pharmaceutically acceptable salt thereof in the dosage from about 70 mg/m/day to about 160 mg/m/day; etoposide in the dosage up to about 100 mg/m/day; and one or more of carboplatin, cisplatin, oxaliplatin, picoplatin, or a combination thereof in the dosage of from AUC 2 mg/mL/min to AUC 7 mg/mL/min; wherein the treatment does not result in a dose limiting toxicity.